

# Competitor Analysis: Targeted Therapy of Hepatitis C

<https://marketpublishers.com/r/C90E2CCCB38EN.html>

Date: August 2011

Pages: 91

Price: US\$ 826.00 (Single User License)

ID: C90E2CCCB38EN

## Abstracts

### Product description

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regimens are genotype dependent and the amount of peg-IFN-? administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In

In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and additional comments with a hyperlink leading to the source of information.

## **Index**

HCV Protease Inhibitors

HCV RNA Polymerase Inhibitors

Cyclophilin Inhibitors

HCV NS5A Protein Inhibitors

HCV NS4B-RNA Binding Inhibitors

Therapeutic & Preventative HCV Vaccines

Therapeutic HCV Antibodies

HCV Viral Entry Inhibitors

HCV Replication Inhibitors

Novel Mechanism of Action HCV Virus & Host Cell Targets

TLR Agonists

Various

Corporate Targeted Hepatitis C Therapeutic R&D Pipelines

About La Merie

## **Corporate Targeted Hepatitis C Therapeutic R&D Pipelines**

Abbott

Achillion Pharmaceuticals

Alios Biopharma

Altor Biosciences

Anadys Pharmaceuticals

Astex Therapeutics

Avila Therapeutics

Bionor Immuno

Biotica Technology

Biotron

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

C-Pharma

Can-Fite BioPharma

Chimerix

ChronTech Pharma

Compass Biotechnologies

Conatus Pharmaceuticals

CureTech

Cytheris

Debiopharm

Dynavax Technologies

Eiger Pharmaceuticals

Enanta Pharmaceuticals

Epiphany Biosciences

Epixis

Genmab

GenPhar

Gilead Sciences

GlaxoSmithKline (GSK)

GlobelImmune

Heat Biologics

Idenix Pharmaceuticals

Idera Pharmaceuticals

Inhibitex

Inovio

Intellektualniy Dialog

Intercell

iTherX Pharmaceuticals

Japan Tobacco

Johnson & Johnson (J&J)

Medivir

Massachusetts Biologic Laboratories (MBL)

Merck & Co

Mitsubishi Tanabe Pharma

Morningside Asia Venture

Novartis

Okairos

Ono Pharmaceutical

Paladin Biosciences

Peregrine Pharmaceuticals

Pfizer

Pharmasset

PTC Therapeutics

Presidio Pharmaceuticals

Progenics Pharmaceuticals

Regulus Therapeutics

Replicor

Roche

Rosetta Genomics

Samaritan Pharmaceuticals

Santaris Pharma

SCYNEXIS

Tacere Therapeutics

TaiGen Biotechnology

Teva Pharmaceutical Industries

Theravance

Transgene

Tripep

Vertex Pharmaceuticals

Viriome

Virionics

ViroBay

**About Competitor Analysis Series:**

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## I would like to order

Product name: Competitor Analysis: Targeted Therapy of Hepatitis C

Product link: <https://marketpublishers.com/r/C90E2CCCB38EN.html>

Price: US\$ 826.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C90E2CCCB38EN.html>